nivolumab,ipilimumab
bms
['melanoma', 'nivo', ' ipi ']
yesterday, in the presidential symposium, phiii trial about tils vs ipi in melanoma 2nd line setting was presented. primary endpoint (pfs) was meet. patients had not received prior nivo+ipi, only antipd1. i think good prognosis patients has also been included #esmo22 #melanoma 
Medical Oncologist. Melanoma and Skin Tumors. Early phase and phase III clinical trials. Hospital Clínic (Barcelona). Opinions are mine.